Description
Product Usage Information
Lenalidomide is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.29 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect. Caution: Teratogenic. May cause harm to the unborn child. Avoid all contact with this product during pregnancy.
Storage
Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
The immunomodulatory drug Lenalidomide is one of a number of chemically modified analogs of the angiogenesis inhibitor, Thalidomide. Lenalidomide can act as an anti-tumor agent by suppressing angiogenesis and activating the immune system (1). Binding of Lenalidomide to Cereblon (CRBN), a substrate receptor for the CRL4 E3 ubiquitin ligase, causes selective ubiquitination and degradation of the zinc finger transcription factors Ikaros and Aiolos (2). A similar mechanism leads to the ubiquitination and targeted degradation of casein kinase 1α (CK1α) (3). Lenalidomide also downregulates SALL4, a zinc finger transcription factor that has been implicated in some human malformation syndromes, including Duane-radial ray syndrome (Okihiro syndrome) and Acro-renal-ocular syndrome (4). Lenalidomide (and other Thalidomide derivatives) can effectively treat multiple myeloma, mantle cell lymphoma, and non-Hodgkin follicular lymphoma (5-7) and can effectively induce remission in patients with myelodysplastic syndrome, either with or without chromosome 5q deletion (8).
Alternate Names
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione; CC-5013
